Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Jae Hui KimYoung Ju Lew

Abstract

To evaluate treatment outcomes of intravitreal vascular endothelial growth factor (VEGF) in eyes with polypoidal choroidal vasculopathy (PCV) that exhibited poor baseline visual acuity. This retrospective, observational study included 47 eyes with treatment-naïve PCV with baseline visual acuity of 20/200 or worse treated with intravitreal anti-VEGF. Eyes were divided into 2 groups according to the presence of submacular hemorrhage (hemorrhage and no-hemorrhage groups). The best-corrected visual acuity (BCVA) at baseline was compared with that measured at 3 and 6 months after treatment. A mean of 3.3±0.9 intravitreal anti-VEGF injections were performed during the 6-month follow-up period. In the hemorrhage group (n=23), 6 patients additionally underwent pneumatic displacement with or without intravitreal tissue plasminogen activator. The logarithm of minimal angle of resolution BCVA at diagnosis, 3, and 6 months was 1.47±0.49, 0.91±0.79, and 0.81±0.83, respectively. Compared with baseline, BCVA was significantly better at 3 and 6 months (P=0.007 and P=0.001, respectively). In the no-hemorrhage group (n=24), the BCVA at defined time points was 1.23±0.32, 1.06±0.33, and 1.02±0.35, respectively. BCVA was significantly better at 3 a...Continue Reading

References

Jan 1, 1990·Retina·L A YannuzziB Lipson
May 7, 2002·American Journal of Ophthalmology·Masanobu UyamaMiyo Matsumura
Jun 4, 2004·Japanese Journal of Ophthalmology·Masami NakajimaRyusaburo Mori
Nov 4, 2004·Ophthalmology·Neil M BresslerUNKNOWN Submacular Surgery Trials (SST) Research Group
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Feb 25, 2011·The New England Journal of Medicine·Deborah A Martin, Sanjaya Senanayake
Jun 21, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jost B JonasFrank C Schlichtenbrede
Apr 3, 2012·American Journal of Ophthalmology·Kenji YamashiroNagahisa Yoshimura
Feb 23, 2013·The British Journal of Ophthalmology·Taiichi HikichiShoko Shioya
Sep 24, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Abdullah OzkayaAhmet Demirok

❮ Previous
Next ❯

Citations

Mar 19, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Young Suk ChangSung Won Cho

❮ Previous
Next ❯

Software Mentioned

Heidelberg Eye Explorer
SLO
OCT viewer
SPSS

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.